AbbVie 2nd-qtr in line with expectations

29 July 2022
abbvie_big-1

US pharma major AbbVie’s (NYSE: ABBV) shares were up 1.5% at $147.50 pre-market, as it announced financial results for the second quarter ended June 30, 2022.

It delivered second-quarter net revenues of $14.583 billion, an increase of 4.5% on a reported basis and 6.1% operationally. This was in line with consensus estimates. Net earnings attributable to AbbVie came in at $924 million, up 20.6% compared with $766 million a year earlier

Diluted earnings per share (EPS) in the second quarter was $0.51 on a GAAP basis. Adjusted diluted EPS, excluding specified items, was $3.37. These results include an unfavorable impact of $0.14 per share related to acquired IPR&D and milestones expense.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical